Structure-guided design of selective Epac1 and Epac2 agonists

Frank Schwede, Daniela Bertinetti, Carianne N Langerijs, Michael A Hadders, Hans Wienk, Johanne H Ellenbroek, Eelco J P de Koning, Johannes L Bos, Friedrich W Herberg, Hans-Gottfried Genieser, Richard A J Janssen, Holger Rehmann

Onderzoeksoutput: Bijdrage aan wetenschappelijk tijdschrift/periodieke uitgaveArtikelWetenschappelijkpeer review

54 Citaten (Scopus)


The second messenger cAMP is known to augment glucose-induced insulin secretion. However, its downstream targets in pancreatic β-cells have not been unequivocally determined. Therefore, we designed cAMP analogues by a structure-guided approach that act as Epac2-selective agonists both in vitro and in vivo. These analogues activate Epac2 about two orders of magnitude more potently than cAMP. The high potency arises from increased affinity as well as increased maximal activation. Crystallographic studies demonstrate that this is due to unique interactions. At least one of the Epac2-specific agonists, Sp-8-BnT-cAMPS (S-220), enhances glucose-induced insulin secretion in human pancreatic cells. Selective targeting of Epac2 is thus proven possible and may be an option in diabetes treatment.

Originele taal-2Engels
Pagina's (van-tot)e1002038
TijdschriftPLoS Biology
Nummer van het tijdschrift1
StatusGepubliceerd - jan. 2015


Duik in de onderzoeksthema's van 'Structure-guided design of selective Epac1 and Epac2 agonists'. Samen vormen ze een unieke vingerafdruk.

Citeer dit